Laguna Pharmaceuticals grabs $30 mln Series B, also appoints CEO

Laguna Pharmaceuticals, formerly known as ChanRx, has closed $30 million in Series B financing. Versant Ventures and Frazier Healthcare led the round with participation from BioMed Ventures and previous backer Sante Ventures. In addition to the financing, Dr. Jerel Davis of Versant Ventures and Dr. Jamie Topper of Frazier Healthcare have been added to Laguna’s board of directors. Also, Laguna Pharmaceuticals has hired Bob Baltera as CEO. Previously, Baltera was CEO of Amira Pharmaceuticals. Laguna Pharmaceuticals is a biopharmaceutical company focused on treating atrial fibrillation and atrial flutter.


Santé Ventures leads $18 mln Series B funding in Claret Medical

Santé Ventures has led an $18 million Series B funding round in Claret Medical, a developer of products for cerebral protection during structural heart, vascular and cardiac surgery procedures. Other investors in the funding round included Lightstone Ventures and Easton Capital. James Eadie from Santé Ventures and Hank Plain from Lightstone Ventures will join Claret Medical’s board of directors.

BAROnova Closes Series C

trong>BAROnova has closed its Series C financing of $27.3 million, led by investments from Sante Ventures and Boston Scientific Corporation, an innovator of medical devices and technologies. Investors included Series B investors ONSET Ventures, Highland Capital Partners and Arboretum Ventures, along with new investor Lumira Capital. Financial terms were not disclosed.

Spinal Restoration Closes $5 Mln Debt, Equity Round

Spinal Restoration said Monday it closed a $5 million financing round, which includes $3 million equity from current investors Austin Ventures, Sante’ Ventures, and MB Venture Partners. Comerica Bank is also providing a $2 million debt facility. Austin-based Spinal Restoration is trying to gain regulatory approval of its Biostat System, a drug used to treat chronic disc pain.

ChanRx Inks Series A

Cleveland-based ChanRx has closed on an undisclosed amount of Series A financing from investors including Sante Ventures. The company is developing drugs to treat atrial fibrillation. Sante Ventures was founded in 2006 and manages $260 million in capital.

Explorys Inks $11.5M Series C

Cleveland-based Explorys has closed on $11.5 million in Series C financing led by Austin Ventures and Foundation Medical Partners, with follow-on investments from Santé Ventures and Cleveland Clinic. Formed in 2009, the company’s integrated healthcare systems are aimed at improving care, costs, and outcomes by leveraging clinical data at scale.

EndoStim Raises $6 Million

EndoStim Inc., a St Louis-based developer of minimally-invasive interventional therapies to treat gastrointestinal and urological neuro-muscular disorders, has raised $6 million in Series B funding. Santé Ventures led the round, and was joined by Prolog Ventures, Vectis Healthcare & Life Sciences Fund and individual angels.

TVA Medical Raises $2.6 Million

TVA Medical Inc., an Austin, Texas-based developer of minimally-invasive therapies for end-stage renal disease, has raised $2.6 million in Series A funding from Santé Ventures.

Sante Ventures Adds One, Promotes Another

Omar Khalil has been promoted to Senior Associate with Santé Ventures, an early-stage life sciences venture capital firm. Meanwhile the firm has added Jim Graham as a Senior Associate. Graham was previously an engagement manager in the Healthcare practice of McKinsey & Company. Press release: Santé Ventures, an early-stage life sciences venture capital firm, announced […]

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget